Cargando…
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposi...
Autores principales: | Tsakaneli, Alexia, Williams, Owen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478155/ https://www.ncbi.nlm.nih.gov/pubmed/34594227 http://dx.doi.org/10.3389/fphar.2021.741413 |
Ejemplares similares
-
Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements
por: Esposito, Maria Teresa, et al.
Publicado: (2022) -
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022) -
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021) -
Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022) -
Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
por: Tregnago, Claudia, et al.
Publicado: (2022)